Remiges created a de novo company based on intellectual properties from a national university in Japan

Remiges Biopharma Fund has a mission to create de novo companies based on disruptive scientific discoveries made in Japanese academic institutions. A significant number of drugs in common use around the world today have their origins in academic institutions in Japan. In addition, Japan ranked between second or fourth in terms of origin of top 100 pharmaceutical products by sales in the global market over the past 15 years (1).

We built a new company from the scratch based on scientific discoveries made by a professor at a prominent national university in Japan and the licensing agreement for the intellectual properties was signed in June this year.

Our virtual drug development team involving talents in drug development across continents will take initiatives in building the company's development strategy and executing the development plan.

1. JPMA News Letter. January 2018 N0.183